

# Research & Reviews:Journal of Medical and Health Sciences

## Immunologic Adjuvants – An Overview

Gopalarao Vuppala\*, Udayalakshmi Pulagam, Divya Anumakonda

Department of Medicinal Chemistry, Vignan College of Pharmacy, Guntur, AP, India

### Review Article

Received: 06/07/2016

Accepted: 26/07/2016

Published: 02/08/2016

#### \*For Correspondence

1-218, Vinukonda, Guntur-522647, Andhra Pradesh, India.

E-Mail:gopal0037@gmail.com

**Keywords:**Adjuvant, Immunogen, Recombinant DNA technology, Saponins.

#### ABSTRACT

With the onset of antigen creation utilizing biosynthetic and rDNA strategies, the need to manage adjuvants alongside immunizations has expanded astoundingly. This quest for going with adjuvants has brought about a large number of atoms from mineral salts to bacterial polysaccharides and Immuno stimulatory edifices that extent significantly in viability. In addition, the adjuvant particle is particular to its antigen atom and henceforth must be custom-made appropriately to boost adequacy and security, keeping up the expense at the very least. This paper investigates the attributes of these particles, their method of activity and the headways in the field.

#### INTRODUCTION

The word adjuvant is gotten from the Latin word *adiuvare*;proposing to help or help, implies any material that updates the cell or humoral response to an antigen. They include a varying social affair of described particles or more personality boggling points of interest, and have been used after the mid twentieth century to improve this response. The necessity for adjuvants has risen in light of the way that various antibodies convey a poor immunological response in solitude [1-7].

#### Necessity for Adjuvants

Antibodies, a standout amongst the best restorative innovations against different irresistible infections, (Hillman), once in a while require a particle in conjugation that expands its insusceptible reaction. Beforehand, antibodies used to be made in light of proteins, starches, complex lipids and nucleic acids secluded from common sources. Nonetheless, the antigens today are made utilizing cutting edge concoction, biosynthetic and rDNA systems;a larger part of which are powerless immunogens because of the absence of a characteristic safe jolt [8-11]. Little polypeptides (<10 kDa) and nonprotein antigens should be conjugated to a vast immunogenic bearer protein to end up great immunogens. It is consequently practical to co-control these with an adjuvant to guarantee a top notch/high amount, memory-improved counter acting agent reaction [12-15].

Adjuvants can be subjected to various uses, for instance,

1. To reinforce the safe reaction of any antigens by conveying in local structure.
2. To decrease the different inoculation convention for defensive resistance. Specifically to create single stride inoculation scope that can diminish the immunization costs.
3. To improve the resistant reaction of safe bargained grown-ups and debilitated insusceptible arrangement of youngsters, to evoke cytotoxic T lymphocytes reaction and produce neighborhood safe reaction [16-22].

#### Arrangement of Adjuvants

The adjuvant property of atom increments with the length of the sugar side chain and the HLB esteem has high hydrophile-lipophile party (HLB) esteem [23]. Nonetheless, adjuvants are routinely grouped into the accompanying classifications:Mineral mixes, Bacterial items, Oil-based emulsions, ISCOMs and Liposomes. Of these, the aluminum based mineral mixes are the most far reaching, and the most favored for people [24-28].

## Aluminum based minerals

Aluminum based adjuvants, similar to Aluminum hydroxide and Aluminum phosphate have been known not early, dependable, high titre, defensive safety. Be that as it may, aluminum is a feeble adjuvant for immune response incitement to recombinant protein immunizations [29-32].

## Oil-based emulsions

These are prevalent safe potentiators for inactivated antibodies [11].

**Saponins:**Saponins are steroid or triterpenoid glycosides, which happen in numerous plant species, in both wild plants and developed products. In developed products the triterpenoid saponins are for the most part dominating, while steroid saponins are regular in plants utilized as herbs or for their wellbeing advancing properties. Saponin-based adjuvants have the exceptional capacity to invigorate cell-interceded insusceptibility, and in addition to improve immune response generation [33-35]. Research on certain conventional Chinese therapeutic herbs, for example, Panax ginseng, Astragalus species, Panax notoginseng have picked up consideration as contender for plant inferred saponins [36,37]. Quillaja saponaria remove as adjuvants, initially depicted in the 1930s have been the most conspicuous of the saponins utilized as adjuvants to highlight as a part of the separate writing [38,39].

## Bacterial Items

Due to their powerful immunostimulatory limit, bacterial items are viewed as a decent wellspring of immunological adjuvants. Bacterial flagellin is a successful adjuvant for CD4+ T cells in vivo [40].

Heat stun proteins (HSPs) are preserved proteins that are very immunogenic and capacity as adjuvants that may assume an essential part in incorporating natural and versatile insusceptibility [41].

## Cytokines

Cytokines like IFN $\gamma$  or GM-CSF have been well known for over 10 years as viable adjuvant atoms [42]. Affectation of neighbourhood deferred touchiness (DTH) is usually seen after the utilization of Pro-incendiary cytokines IL-1, TNF-, IFN-, IFN-, IL-6, IL-8 [43].

## Determination of Adjuvants

Immunological adjuvants quicken, delay or upgrade antigen-particular invulnerable reactions if utilized as a part of mix with particular immunization antigens. In a perfect world an adjuvant is expected to have long time span of usability with undiminishing strength, biodegradability, minimal effort of creation, the capacity to not affect resistant reactions against itself and to advance the required invulnerable reaction. Notwithstanding, perceptions have been made of contrasts in adjuvant adequacy with the course of organization e.g. amongst mucosal and parenteral courses. Subsequently, the adjuvant ought to be chosen by considering the different components included [44-46]. For instance, it was found that subunit antibody reactions can be improved with respect to dissolvable antigen/adjuvant or alum details. Kreuter and Haenzel, watched that the molecule size of the polymer adjuvant was observed to be a critical parameter for adjuvant movement [47-50].

## Method of Action of Adjuvants

Antibodies in light of profoundly sanitized antigens will require particular adjuvants to evoke the required reaction [51]. Focusing of immunizations to particular safe cells is extremely encouraging. Be that as it may, it might be hard to create compelling immunizations without blocking resistant administrative pathways in this manner hampering the CMI reaction. Adjuvants effects the invulnerable reactions, and can tip the resistant framework for Th1 or Th2 sort reaction [52-54].

To support an Ab reaction, a supply of Ag is required. One way an adjuvant may help the invulnerable reaction is by shaping a station of Ag at the infusion site bringing about the supported arrival of little amounts of Ag over a drawn out stretch of time. Indeed, even with an adjuvant that structures a stop of Ag, sooner or later in time the amount of Ag is reduced and the Ab titer decays [55-58]. As of now a second infusion of Ag (a sponsor dosage) might be given. At the point when a creature that has reacted maximally is given a supporter dosage of Ag too early, concealment as opposed to upgrade of the insusceptible reaction may follow [60,61].

On the other hand, an adjuvant can work is to serve as a vehicle to convey the Ag to the spleen and/or lymph hubs where Ag is caught by the follicular dendritic cells and where the greater part of the vital cell to cell communications occur to produce plasma cells (the Ab-emitting cells) [62-64]. For instance, microdroplets of oil

containing Ag, for example, those shaped in an oil-in-water adjuvant emulsion, are promptly ingested by macrophage and taken to depleting lymph hubs or spleen. Ag-stacked tissue dendritic cells quickly immigrate by means of lymphatics to depleting lymph hubs. Furthermore, emulsions help tissue dendritic cells in their catch of Ag [65-69].

A third way an adjuvant can work is to actuate the different cells required in the insusceptible reaction, either straightforwardly or by implication. Surfactants, segments of all emulsion adjuvants, may serve this capacity and balancing out oil-water emulsions. Additionally, numerous microscopic organisms contain substances that initiate cells of the insusceptible framework, especially the macrophage [70]. The enacted macrophage thus actuates T and B cells. Along these lines a few adjuvants contain microbes, bacterial items, or subsidiaries of bacterial items. Despite the fact that the initiation of macrophages to be sure guides in the immune response reaction, unreasonable actuation of macrophages additionally causes exorbitant aggravation, so that bacterial segments can't be utilized as a part of overabundance. As of late, various bacterial items have been altered in ways that expand their attractive initiation potential and minimize their provocative potential with the objective of discovering perfect adjuvant segments [71-73]. For instance, a portion of the new era adjuvants consolidate a substance variation of endotoxin called monophosphoryl lipid A [MPL] or an adjusted muramyl dipeptide [thr-MDP] or other "detoxified" cell divider constituents of microscopic organisms [74,75].

## PROGRESSIONS

Adjuvant definitions can be custom fitted to improve the required resistant reaction (neutralizer, cell intervened, mucosal safety) particular to individual causative irresistible specialists [76-81].

The Matrix Immune Modulator (MIM) was created to defeat genuine and saw impediments of established mineral salt adjuvants. It potentiated the insusceptible reaction to antigens as well as expanded counter acting agent creation in chickens and mice, hence proposing MIMs as a potential substitute for mineral based adjuvants [77-80]. Analyzed a steady oil-in-water emulsion (SE) and a steady oil-in-water emulsion fusing glucopyranosyl lipid adjuvant, an engineered TLR-4 agonist (GLA-SE), each together with a recombinant protein, ID93. Their study highlighted the accentuation on managing powerful adjuvants alongside the subunit immunizations for treatment against tuberculosis [85-90].

BAE, or organically dynamic particles sanitized from a Brazilian palm-tree natural product the babassu, have been appeared to have potential adjuvant properties. Research recommends that it could be controlled in relationship with or without aluminum mixes, for the particular incitement of Th1-ward invulnerable reactions against various antigens in unmistakable murine strains and creature species [91-93].

Adjuvants are being concentrated on for the treatment of cutaneous melanoma. Oncogenic BRAF inhibitors, for example, vemurafenib have been proposed to be utilized as a part of the adjuvant setting [94-97].

The immunologic improvement interceded by a polysaccharide (PPSB) from the products of *Physalis alkekengi* yielded results which showed that both humoral insusceptibility and cell resistance were intervened by the polysaccharide. It is subsequently a promising adjuvant evoking both Th1 and Th2 reactions to enhance the adequacy of antibody [98-100].

## PROGRAMMING THAT AIDS ADJUVANT SELECTION

Adjuvant virtual products have been created to give an assessment of regardless of whether to get system

## REFERENCES

1. Ramezani B, et al. Cross-Sectoral Perspectives of Market Implementation of the MVA Platform for Influenza Vaccines:Regulatory, Industry and Academia. *J Vaccines Vaccin* 2016;7:318
2. Kiseleva I, et al. Potentially Pandemic Live Influenza Vaccines Based on Russian Master Donor Virus are Genetically Stable after Replication in Humans. *J Vaccines Vaccin* 2016;7:317
3. Bharmoria A, et al. A Retrospective Surveillance Study on Emergence and Consistency of Influenza like Illness Caused by Influenza Strains over a Period of Three Decades in Solan, (Himachal Pradesh), India. *J Med Microb Diagn* 2016;5:216.
4. Palache B. Commentary on Seasonal Influenza Vaccine Dose Distribution in 195 countries (2004-2013):Little Progress in Estimated Global Vaccination Coverage. *J Vaccines Vaccin* 2016;7:308.
5. Roos A, et al. Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies. *Vaccine* 2015;33:1739-1747.

6. Puchalski S, et al. Current Attitudes and Practices among Pregnant Women toward Influenza Immunization. *J Preg Child Health* 2016;2:184.
7. Li X, et al. Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus. *J Vaccines Vaccin* 2015;6.
8. Masoudi S, et al. Is there an Association between the H1N1 Influenza Pandemic Vaccination and the Manifestation of Narcolepsy?. *J Vaccines Vaccin* 2016;6:280.
9. Madar-Balakirski N, et al. Measurement of Cellular Immunity to Influenza Vaccination in Rheumatoid Arthritis; Comparison of Three Assays. *J Vaccines Vaccin* 2016;6:278.
10. Zheng T, et al. (2015) Adjuvanticity of a Synthetic Phosphatidylinositol Dimannoside to a Subvirion Influenza Vaccine in an Influenza Mouse Model. *J Vaccines Vaccin* 2016;6:277.
11. Shizuma T. Autoimmune Hemolytic Anemia Following Influenza Virus Infection or Administration of Influenza Vaccine. *J Blood Disord Transfus* 2016;5:200.
12. Shizuma T. Immune Thrombocytopenia Following Influenza Virus Infection and Influenza Vaccine Administration. *Virology & Mycology* 2016;S2:003.
13. Davidson HA, et al. Knowledge, Attitudes and Practices Regarding 2009 H1N1 Vaccine Among Patients Hospitalized With Influenza A (H1N1) pdm09. *Virology & Mycology* 2013;S2:002.
14. Baldo V, et al. Immunogenicity and Safety of an MF59®-Adjuvanted and a Non-Adjuvanted Inactivated Subunit Influenza Vaccine in Adults Affected by Chronic Diseases. *J Clin Trials* 2012;2:112.
15. Cano M, et al. Bell's Palsy Cases Following Administration of Influenza A (H1N1) 2009 Monovalent Vaccine Reported to the Vaccine Adverse Event Reporting System (VAERS). *J Vaccines Vaccin* 2012;3:134.
16. Burel JG, et al. Evaluation of Immune Responses to Influenza Vaccination in Chronic Obstructive Pulmonary Disease. *J Vaccines Vaccin* 2012;S4:001.
17. Chen S, et al. Human CD4+ Memory T-cell Populations Secrete Th1 Cytokines in Response to Influenza Antigen Stimulation. *J Vaccines Vaccin* 2016;3:129.
18. Eichelberger MC, et al. Qualitative Differences in T cell responses to Live, Attenuated and Inactivated Influenza Vaccines. *J Clin Cell Immunol* 2016;S4:002.
19. Handler MZ, et al. Granulomatous Reaction Confined to Two Blue-ink Tattoos after H1N1 Influenza Vaccine. *J Vaccines Vaccin* 2016;1:108.
20. Vathsala PG. Protection after Malaria Therapy: A Step-up to Immunity. *Malaria Contr Elimination* 2016;5:148.
21. Maes R. Can the Triumphant March of TB be Stopped? A Critical Appraisal of the Currently Applied Policy of Eradication. *Clin Microbiol* 2016;5:255.
22. Maes R. A Critical Appraisal of the Ban on Serological Tests for Tuberculosis Usefulness of Serological Monitoring of Tuberculosis Antibodies during the Treatment of TB Patients. *Clin Microbiol* 2016;5:254.
23. Prosser N, et al. Survey of Australian Father's Attitudes towards Infant Vaccination: Findings from the Australian Father's Study. *Primary Health Care* 2016;6:228.
24. Asif S, et al. Intervening Swine Flu Epidemic. *J Bioequiv Availab* 2016;8:194-196.
25. Ali SA, et al. Surveillance System Proposed to Monitor the Burden of Diarrheal Diseases in Pakistan: A Short Communication. *J Gen Practice* 2016;4:258.
26. Varshney A, et al. Development of Recombinant Domains of Protective Antigen of Bacillus anthracis and Evaluation of their Immune Response in Mouse Model for Use as Vaccine Candidates for Anthrax. *J Bioterror Biodef* 2016;7:147.
27. Pugholm LH, et al. Antibody-Mediated Delivery of Antigen to Dendritic Cells. *Immunother Open Acc* 2016;2:119.
28. Mortensen R and Dietrich J. New Generation Combination Vaccines against Streptococcus pyogenes. *J Vaccines Vaccin* 7:323.

29. Kumar JS, et al. Assessment of Immunogenic Potential and Protective Efficacy of Recombinant Whole Envelope and Domain III Subunit Vaccine Candidate against West Nile Virus. *Int J Pub Health Safe* 2016;1:106.
30. Chamcha V. Probiotics Based Approaches to Target Mucosal Compartments: Potential Novel Approaches to HIV Vaccine Development. *J AIDS Clin Res* 2016;7:e119.
31. Bueno J. Antimicrobial Adjuvants Drug Discovery, the Challenge of Avoid the Resistance and Recover the Susceptibility of Multidrug-Resistant Strains. *J Microb Biochem Technol* 2016;8:169-176.
32. Huang SM, et al. Establishment and Characterization of a Novel Kidney-cell Line from Orange-spotted Grouper, *Epinephelus coioides*, and its Susceptibility to Grouper Iridovirus. *J Marine Sci Res Dev* 2016;6:192.
33. Gary J, et al. Extending Life: From Stem Cells to Gene Therapy. *J Clin Med Genom* 2016;4:140.
34. Huicab-Pech ZG, et al. Current State of Bacteria Pathogenicity and their Relationship with Host and Environment in *Tilapia Oreochromis niloticus*. *J Aquac Res Development* 2016;7:428.
35. Kaihatsu K, et al. Future Perspective of Nucleic Acid-based Detection of Dengue Virus and its Serotypes. *J Antivir Antiretrovir* 2016;8:LXIX-LXXII.
36. Kunimoto M, et al. Influence of Pneumococcal Conjugate Vaccine on Otitis Media. *Otolaryngol (Sunnyvale)* 2016;6:236.
37. Goh YS, et al. IgG Subclasses Targeting the Flagella of *Salmonella enterica* Serovar Typhimurium can Mediate Phagocytosis and Bacterial Killing. *J Vaccines Vaccin* 2016;7:322.
38. Maldarelli GA, et al. Pilin Vaccination Stimulates Weak Antibody Responses and Provides No Protection in a C57Bl/6 Murine Model of Acute *Clostridium difficile* Infection. *J Vaccines Vaccin* 2016;7:321.
39. Sugun MY, et al. Isolation of Uncommon *Pasteurella multocida* Strains from Cattle in North Central Nigeria. *J Vaccines Vaccin* 2016;7:320.
40. Singh R, et al. Reverse Vaccinology: Developing Vaccine Against MDR *Acinetobacter baumannii*. *J Vaccines Vaccin* 2016;7:419.
41. Ramezanpour B, et al. Cross-Sectoral Perspectives of Market Implementation of the MVA Platform for Influenza Vaccines: Regulatory, Industry and Academia. *J Vaccines Vaccin* 2016;7:318.
42. Kiseleva I and Rudenko L. Potentially Pandemic Live Influenza Vaccines Based on Russian Master Donor Virus are Genetically Stable after Replication in Humans. *J Vaccines Vaccin* 7:317.
43. Liu ZQ and Zheng PY. DNA Vaccines: The New Directions to Allergic Diseases. *J Allergy Ther* 2016;7:e114.
44. AbdAllah AAA, et al. Awareness and Attitudes of Nursing Students towards Prevention of Cervical Cancer. *Cervical Cancer* 2016;1:107.
45. Bhattacharyya S, et al. Modulating the Glucose Transport by Engineering Gold Nanoparticles. *J Nanomedicine Biotherapeutic Discov* 2016;6:141.
46. Weltman JK. An Immuno-Bioinformatic Analysis of Zika virus (ZIKV) Envelope E Protein. *J Med Microb Diagn* 2016;5:228.
47. Kebede B, et al. Review on Current Status of Vaccines against Parasitic Diseases of Animals. *J Veterinar Sci Techno* 2016;7:327.
48. Singh SV, et al. *Gallibacterium anatis*: An Emerging Pathogen of Poultry Birds and Domiciled Birds. *J Veterinar Sci Techno* 2016;7:324.
49. Geresu MA and Kassa GM (2016) A Review on Diagnostic Methods of Brucellosis. *J Veterinar Sci Techno* 7:323.
50. Xiaodong S, et al. Knowledge and Attitude toward Pneumonia and Pneumococcal Polysaccharide Vaccine among the Elderly in Shanghai, China: A Cross-sectional Questionnaire Survey. *J Pulm Respir Med* 2016;6:330.

51. Selvakkumar C, et al. Nanopeptides:Non - Covalent Interactions in Chemistry and Biological Functions. *J App Pharm* 2016;8:218.
52. Mani VSS, et al. Design, Synthesis and Development of Stereo Chemical Constraints into  $\beta$  -Amino Acid Residues:Gabapentin Structural Data Role in Nerve Pain Medication. *J App Pharm* 2016;8:217.
53. Rennou M, et al. Antibodies against BCG and M. tuberculosis H37Ra do not Consistently Recognize Pathogenic M. tuberculosis whole Cells but Recognize their Cytoplasmic Constituents. Implications for the Variability and Protective Efficacy of the Vaccine. *Clin Microbiol* 2016;5:246.
54. Mishra S, et al. Prediction of Antigenic MHC Peptide Binders and TAP Binder of COX1 Protein through in silico Approach. *J Drug Metab Toxicol* 2016;7:201.
55. Zhang XS, et al. Seasonal Influenza Vaccination:Its Expected and Unexpected Effects. *J Vaccines Vaccin* 2016;7:314.
56. Appavu R. Nanovaccine Development for Cocaine Addiction:Immune Response and Brain Behaviour. *J Vaccines Vaccin* 2016;7:313.
57. Pant GR, et al. A Serological Study in Response to People at Occupational Risk of Rabies Virus Exposure in Nepal. *J Vaccines Vaccin* 2016;7:312.
58. Pillai TG, et al. Bacterial Polysaccharides - Potential Candidate for Vaccine Development. *J Med Microb Diagn* 2016;5:224.
59. Shimodaira S, et al. An update on Dendritic Cell-Based Cancer Immunotherapy. *Immunome Res* 2016;12:106.
60. Mishra S, et al. Study of Hydrophobicity and Prediction of Antigenic Epitope of NADH dehydrogenase subunit 5 from *D. medinensis*. *Drug Des* 2016;5:127.
61. Appavu R, et al. Fundamental of Secondary Structures in Peptide Based Synthetic Nanovaccine Development. *Transcriptomics* 2016;4:131.
62. Hassan M, et al. A Computational Analysis to Construct a Potential Post-Exposure Therapy against Pox Epidemic Using miRNAs in Silico. *J Bioterror Biodef* 2016;7:140.
63. Muktar Y, et al. Present Status and Future Prospects of Fish Vaccination:A Review. *J Veterinar Sci Technol* 2016;7:299.
64. Olaya N, et al. Bovine Leukemia:Zoonosis Associated with Breast Cancer in Humans?. *J Med Surg Pathol* 2016;1:110.
65. Bharmoria A, et al. The emergence and consistency of influenza strains causing influenza like illness in Himachal Pradesh, India. *Virusdisease* 2016;27:130-135.
66. Yousefi N, et al. Bordetella Bronchiseptica in a Kidneypancreas Transplant Recipient after Dog Vaccination. *J Kidney* 2016;2:120.
67. García CLDG. Importance to Vaccination Against Rabies in Travellers to Areas of Risk. *J Vaccines Vaccin* 2016;7:311.
68. Ito F, et al. Pre-resectional Radiofrequency Ablation as a Neoadjuvant in situ Tumor Vaccine. *J Vaccines Vaccin* 2016;7:310.
69. Shimodaira S, et al. Quality Verification of Dendritic Cell-Based Cancer Vaccine. *Pharm Anal Acta* 2016;7:465.
70. Mishra S, et al. Identification of Antigenic Determinants, Solvent Accessibility and MHC Binders of Antigen NADH Dehydrogenase Subunit 5 from a Little Dragon from Medina (*Dracunculus medinensis*). *Drug Des* 2016;5:126.
71. Regan AK, et al. Seasonal Trivalent Influenza Vaccination during Pregnancy and the Incidence of Stillbirth:Population-Based Retrospective Cohort Study. *Clin Infect Dis* 2016;62:1221-1227.
72. Tartof SY, et al. Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients:A Cohort Study. *Ann Intern Med* 2016;164:593-599.

73. Lin CJ, et al. Association of State Laws and Healthcare Workers' Influenza Vaccination Rates. *J Natl Med Assoc* 2016;108:99-102.
74. Jones KM, et al. Efforts to Improve Immunization Coverage during Pregnancy among Ob-Gyns. *Infect Dis Obstet Gynecol* 2016;2016:6120701.
75. Thompson MG, et al. Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013:The Importance of Two Priming Doses. *Pediatr Infect Dis J* 2015;35:299-308.
76. Ludvigsson JF, et al. Maternal vaccination against H1N1 influenza and offspring mortality:population based cohort study and sibling design. *BMJ* 2016.
77. Achtymichuk KA, et al. Characteristics and health behaviors of diabetic patients receiving influenza vaccination. *Vaccine* 2015;33:3549-3555.
78. Srivastav A, et al. Influenza vaccination coverage of Vaccine for Children (VFC)-entitled versus privately insured children, United States, 2011-2013. *Vaccine* 2015;33:3114-3121.
79. Nace DA, et al. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. *J Infect Dis* 2015;211:1915-1924.
80. Cheung S, et al. Parental perceptions and predictors of consent for school-located influenza vaccination in urban elementary school children in the United States. *Influenza Other Respir Viruses* 2015;9:255-262.
81. Foppa IM, et al. Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14. *Vaccine* 2015;33:3003-3009.
82. Nowak GJ, et al. Promoting influenza vaccination:insights from a qualitative meta-analysis of 14 years of influenza-related communications research by U.S. Centers for Disease Control and Prevention (CDC). *Vaccine* 2015;33:2741-2756.
83. Cadorna-Carlos JB, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults:A randomized, controlled, phase III trial. *Vaccine* 2015;33:2485-2492.
84. Yoo BK, et al. Decomposing racial/ethnic disparities in influenza vaccination among the elderly. *Vaccine* 2015;33:2997-3002.
85. Haber P, et al. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014. *Vaccine* 2015;33:1987-1992.
86. Chen Q, G et al. Influenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged above 50 years. *J Infect Dis* 2015;211:1045-1050.
87. Gorse GJ, et al. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. *Vaccine* 2015;33:1151-1159.
88. Chit A, et al. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. *Vaccine* 2015;33:734-741.
89. Belongia EA, et al. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. *Vaccine* 2015;33:246-251.
90. Nace DA, et al. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. *J Infect Dis* 2015;211:1915-1924.
91. Nyhan B and Reifler J. Does correcting myths about the flu vaccine work? An experimental evaluation of the effects of corrective information. *Vaccine* 2015;33:459-464.
92. Darvishian M, et al. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people:a meta-analysis of test-negative design case-control studies. *Lancet Infect Dis* 2014;14:1228-1239.
93. Chen Q, et al. Influenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged =50 years. *J Infect Dis* 2015;211:1045-1050.

94. Lindley MC, et al. Qualitative evaluation of Rhode Island's healthcare worker influenza vaccination regulations. *Vaccine* 2015;32:5962-5966.
95. Ambrose CS, et al. Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity. *Vaccine* 2014;32:5546-5548.
96. Maurer J, et al. Can routine offering of influenza vaccination in office-based settings reduce racial and ethnic disparities in adult influenza vaccination?. *J Gen Intern Med* 29:1624-1630.
97. Pitts SI, et al. A systematic review of mandatory influenza vaccination in healthcare personnel. *Am J Prev Med* 2014;47:330-340.
98. DiazGranados CA, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med* 2014;371:635-645.
99. Yuen CY and Tarrant M. Determinants of uptake of influenza vaccination among pregnant women - a systematic review. *Vaccine* 2014;32:4602-4613.
100. Pellegrino P, et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies. *Vaccine* 2014;32:4730-4735.